kinase (JNK), leading to the cytoskeletal reorganization, thereby regulating the cellular polarity and migration. [10] [11] [12] [13] Wnt5a-Ror2 signaling also induces expression of receptor activator of nuclear factor-κB (RANK) by activating JNK in osteoclast precursor cells, 14 thereby enhancing RANK ligand (RANKL)-induced osteoclast differentiation. However, molecular mechanisms of cell proliferation mediated by Ror1 and Ror2 still remain largely unknown.
Ror1 and Ror2 are expressed highly in the developing embryos with both overlapping and distinct spatiotemporal expression patterns, and their expression levels are decreased after birth and barely detectable in adulthood. 15, 16 However, recent findings have revealed that Ror1 and/or Ror2 are expressed in the tissue stem cells not only during the embryonic development but also in adulthood. [17] [18] [19] [20] [21] [22] In the adult skeletal muscles, Ror1 is expressed selectively in the adult muscle stem cells, known as satellite cells (SCs), and its expression in SCs can be further enhanced after muscle injury, leading to increased proliferation of SCs, thereby promoting regeneration of the damaged skeletal muscles. 20 In addition, expression of Ror2 is increased in reactive astrocytes that acquire stem cell-like properties in the injured brains, leading to increased proliferation of reactive astrocytes, thereby promoting repair following brain injury. 23 Astrocytes are mitotically quiescent in the adult brains, but start their cell cycle in response to growth factors, such as basic fibroblast growth factor (bFGF), in the injured brains. It has been shown that expression of Ror2 is increased in cultured astrocytes stimulated with bFGF, and that Ror2 is required for bFGF-induced cell cycle progression of astrocytes. 23 Accumulating evidence further demonstrates that Ror2 is expressed highly in various types of cancer cells, and plays critical roles in regulating proliferation as well as migration and invasion of these cancer cells. [24] [25] [26] [27] In cells stimulated with growth factors or cells harboring mutations in tumor suppressor genes like p53, retinoblastoma protein (Rb) is heavily phosphorylated by activated cyclin-dependent kinases (CDKs), leading to activation of E2F transcription factors to promote the cell cycle progression from G1 to S phase. [28] [29] [30] [31] [32] [33] It has been shown that the suppressed expression of Ror2 results in reduced G1/S phase transition in astrocytes and cancer cells. 23, 26 However, it remains unclear about the molecular basis of how Ror2 expression is induced in proliferating cells, and how Ror2 regulates the cell cycle progression.
Here, we show that Ror2 is transcriptionally induced by activation of E2F1 during bFGF-induced cell cycle progression in NIH/3T3 fibroblasts. We also performed RNA-seq analysis to survey genes whose expression is affected (upregulated or downregulated) by suppressed expression of Ror2 in bFGF-stimulated NIH/3T3 cells. It was found that expression of E2F target genes and of Forkhead box O (FoxO) target genes are decreased and increased, respectively, by suppressed expression of Ror2. These findings demonstrate for the first time that the expression of Ror2 is induced by E2F1, and that Ror2 mediates transcriptional activation of cell cycle-regulated genes to promote G1/S phase transition in bFGF-stimulated NIH/3T3 cells.
| MATERIALS AND METHODS

| Cell culture and transfection
NIH/3T3 cells were maintained in DMEM (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan) supplemented with 10% (v/v) FBS. To establish NIH/3T3 cells stably expressing ERT2-E2F1, NIH/3T3 cells were infected with retroviruses encoding ERT2-E2F1-WT or ERT2-E2F1-ΔC, followed by selection with puromycin (2 μg/mL; Nacalai Tesque, Kyoto, Japan). Cells were serum-starved in Opti-MEM (Thermo Fisher Scientific, Waltham, MA) for 24 hours, and then stimulated with bFGF (20 ng/mL; FUJIFILM Wako Pure Chemical Corporation) for the indicated periods. In some experiments, cells were stimulated with bFGF along with recombinant Wnt5a (100 ng/mL; R&D Systems, Minneapolis, MN). To induce activation of ER-E2F1, cells were treated with 4-hydroxytamoxifen (OHT) (300 nM; Sigma-Aldrich, St. Louis, MO) for 4 hours. To arrest cell cycle progression, serum-starved cells were treated with bFGF along with doxorubicin (0.2 μg/mL; Sigma-Aldrich). Expression of Ror2, Wnt5a, and FoxO3a, were suppressed by transfection of cells with the respective siRNA oligonucleotides (20 nM) by Lipofectamine RNAiMax Reagent (Thermo Fisher Scientific). Silencer select siRNAs targeting mouse Ror2 (si-Ror2#1, s77263; Ror2#2, s77265), p27 Kip1 (si-p27, s63814) and Wnt5a (si-Wnt5a, s76087) and their control siRNA (Silencer select negative control No. 1, cat. No. 4390843) were purchased from Thermo Fisher Scientific. siRNAs targeting mouse p21 Cip1 (si-p21#1, SASI_ Mm02_00306392; si-p21#2, SASI_Mm02_00306393), CyclinG2 (si-CyclinG2#1, SASI_Mm01_00054926; si-CyclinG2#2, SASI_Mm01_00054927), and FoxO3a (si-FoxO3a, SASI_Mm02_00324883) and their control siRNA (Mission siRNA universal negative control, Cat. No. SIC_001) were purchased from Sigma-Aldrich.
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The amounts of the respective mRNAs were normalized relative to those of 18S ribosomal RNA. Primers used are listed in Table 1 .
| Chromatin immunoprecipitation (ChIP) assay
Cells (1 × 10 6 cells per sample) were fixed with 1% (w/v) PFA for 5 minutes at RT, followed by incubation with 125 mM glycine for 5 minutes at RT. After washing twice with ice-cold PBS, cells were collected by centrifugation (1000 g) for 10 minutes at 4°C, and digested with 0.5 U of micrococcal nuclease (MNase; Takara Bio) in 100 μL of MNase digestion buffer [50 mM Tris-HCl (pH 8.0), 0.2% TritonX-100, and 1 mM CaCl 2 ] for 15 minutes at 37°C. After stopping the reaction by adding 10× MNase stop buffer [110 mM Tris-HCl (pH 8.0) and 55 mM EDTA], the reaction solutions containing digested chromatin were further sonicated for six cycles (30 seconds on/off at high power) by a cup horn sonicator (Q700, Qsonica), adjusted to RIPA condition by adding ice-cold 2× RIPA buffer [280 mM NaCl, 1.8%
(v/v) TritonX-100, 0.2% SDS, 0.2% sodium deoxycholate, 5 mM EGTA, 2 mM p-Amidinophenylmethanesulfonyl fluoride (p-APMSF), 20 μg/mL leupeptin, 20 μg/mL aprotinin and 20 mM sodium butyrate], and then subjected to immunoprecipitation with anti-E2F1 (sc-251, Santa Cruz Biotechnology, Dallas, TX) or control mouse IgG (015-000-003, Jackson ImmunoResearch Laboratories). After decrosslinking and purification of the DNA fragments, the amounts of the DNA fragments of interest were measured by LightCycler 480 II System with a primer pair (5′-CAAGGGACGCCTAGTTAATG-3′ and 5′-GACTTCTAGGCACAAAGGTG-3′) for Ror2 promoter and normalized relative to those in input materials.
| Luciferase reporter assay
Mouse Ror2 promoter regions from −224 to +40 bps or from −71 to +40 bps were subcloned into pGL4.10 [Luc] vectors (Promega, Madison, WI), respectively. These Luc vectors or an empty Luc vector were co-transfected with pRL-TK (Promega) into NIH/3T3 cells expressing 
| Flow cytometry
Cells (1 × 10 5 cells per sample) were fixed in 70% (v/v) ethanol, treated with 100 μg/mL RNase A (Thermo Fisher Scientific) and 50 μg/mL propidium iodide (Sigma-Aldrich), and analyzed on a BD-LSRFortessa X-20 flowcytometer (BD Biosciences, San Jose, CA).
| EdU incorporation analysis
To label cells entering S phase following bFGF stimulation, serum-starved cells were cultured with bFGF in the presence of EdU (10 µM) for 12, 24, or 36 hours. Then, cells were fixed with 4% (w/v) PFA for 10 minutes at room temperature. EdU incorporation was detected using Click-it EdU imaging kit (Thermo Fisher Scientific) according to the manufacturer's instructions.
| Immunocytochemistry
For immunofluorescence analysis, cells were fixed with 4% (w/v) PFA for 30 minutes at room temperature. After treatment with blocking buffer (PBS, containing 3% (w/v) BSA and 0.2% (v/v) Triton X-100), cells were incubated with anti-FoxO3a antibody (#12829, 1:200, Cell Signaling Technology). Alexa Fluoro 488 was used as a secondary antibody and the nucleus was stained with DAPI. Fluorescent images were obtained using a Laser scanning confocal imaging system (LSM710; Carl Zeiss, Oberkochen, Germany). The ratio of mean fluorescence intensity of nuclear FoxO3a to cytoplasmic FoxO3a was determined and quantified using the Intensity Ratio Nuclei Cytoplasm Tool plugin of Image J (NIH, USA).
| RNA-seq analysis
Total RNAs were extracted from cultured cells using the RNeasy Mini kit (Qiagen, Hilden, Germany). AmpliSeq libraries were constructed using the Ion AmpliSeq Transcriptome Mouse Gene Expression Kit (Thermo Fisher Scientific) that is designed for targeted amplification of over 20 000 mouse RefSeq genes simultaneously in a single primer pool. For each sample, 100 ng of total RNA was used for cDNA library preparation. Libraries were clonally amplified using the Ion OneTouch 2 System (Thermo Fisher Scientific), and then sequenced on an Ion Torrent PGM (Thermo Fisher Scientific) using the 318 ChIP. RNA-seq reads were mapped to the reference genome (mouse: GRCm38) and differential expression analysis was performed using CLC bio Genomics Workbench Version 12.0 (CLC Bio, Aarhus, Denmark). An absolute log2 fold change ≥0.5 and q-value (FDR-adjusted P value) <.05 were set as the thresholds for differentially expressed genes (DEGs) detection. Gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analyses were performed by uploading the upregulated and downregulated gene lists into the database for annotation, visualization, and integrated discovery programs.
| Statistical analysis
Data were analyzed using the GraphPad Prism 5.0 (GraphPad Software) and are presented as the mean ± standard deviation (SD). Significance was determined as *P < .05, **P < .01, or | 3417 ENDO Et al.
***P < .001 compared with control using the Student's t test when two groups were compared, or using one-way ANOVA followed by Dunnett's post hoc test when more than three groups were analyzed.
| RESULTS
| Expression of Ror2 is induced by stimulation with either serum or bFGF
We have previously shown that the expression levels of Ror2 in cultured astrocytes are induced during their cell cycle progression from G1 to S phase following bFGF stimulation. 23 As an attempt to elucidate the molecular mechanism underlying the cell cycle-related expression of Ror2 and its possible role in the cell cycle progression, we utilized NIH/3T3 fibroblasts whose cell cycle can be readily controlled by serum-deprivation and subsequent stimulation with serum or growth factors, including bFGF. It was found that endogenous mRNA levels of Ror2 in serum-starved NIH/3T3 cells were lower than those in cells cultured in mediun containing 10% (v/v) FBS, and were increased following bFGF stimulation, whereas mRNA levels of Ror1 in NIH/3T3 cells were unaffected by serum starvation or bFGF stimulation ( Figure 1A ). NIH/3T3 cells were arrested at G1 phase upon serum-starvation, and their cell cycle could be restarted following bFGF stimulation ( Figure S1 ), indicating that, like astrocytes, Ror2 expression in NIH/3T3 cells is induced during bFGF-induced cell cycle progression. bFGF-induced increase in Ror2 mRNA was detected within 4 hours and persisted during the progression from G1 to S phase of the cell cycle along with increased expression of Cyclin D1, Cyclin E1, and Cyclin A2 ( Figure 1B ). To further elucidate the relationship between the expression of Ror2 and cell cycle progression, we examined the effect of bFGF stimulation on expression of Ror2 in NIH/3T3 cells treated with doxorubicin, which prevents bFGF-induced cell cycle entry to S phase 34 ( Figure S1 ). As shown in Figure 1C , bFGF-induced increase in Ror2, Cyclin E1, and Cyclin A2 mRNAs, but not Cyclin D1 mRNA, were significantly suppressed by doxorubicin treatment, suggesting that expression of Ror2 might be associated with entry to S phase mediated by bFGF-induced signaling.
| E2F1 mediates bFGF-induced expression of Ror2
Since mouse Ror2 promoter contains several putative E2F binding sites ( Figure 2A and Table 2 ) and the corresponding nucleotide sequences of mouse and human Ror2 promoter are highly conserved (data not shown), we next examined the possible involvement of E2F1 in regulating expression of Ror2.
To this end, we expressed estrogen receptor-E2F1 fusion protein (ERT2-E2F1) in NIH/3T3 cells and analyzed the effect of E2F1 activation on expression of Ror2. ERT2-E2F1 is expressed as nonfunctional fusion protein in the cytoplasm, and it rapidly translocates into the nucleus and transactivates E2F1 target genes by an addition of OHT. 35 Nuclear translocation of ERT2-E2F1 (wild-type) (E2F1-WT), but not ERT2-E2F1 mutant with the C-terminal transactivation domain deletion (E2F1-ΔC), by an addition of OHT, led to an increased expression of Ror2 mRNA within 4 hours ( Figure 2B ). In contrast, treatment with ethanol (vehicle alone) did not show any apparent effect on expression of Ror2 in NIH/3T3 cells expressing ERT2-E2F1-WT ( Figure S2A ). Consistent with the effect of bFGF stimulation, expression levels of Ror1 were unaffected by OHT-induced E2F1 activation in NIH/3T3 cells expressing ERT2-E2F1-WT ( Figure 2C ). ChIP analysis of the Ror2 upstream region demonstrated that ERT2-E2F1 binds to Ror2 promoter following treatment with OHT, but not its vehicle ( Figures 2D and S2B ). Any apparent binding was undetected with control IgG immunoprecipitation ( Figure 2D ). To determine whether E2F1 activates the promoter of Ror2, luciferase reporter constructs driven by mouse Ror2 promoter fragments (−224/+40 and −71/+40) that contain several putative E2F-binding sites were transfected into NIH/3T3 cells expressing ERT2-E2F1-WT. In agreement with the data obtained by ChIP analysis, the luciferase activity driven by −224/+40 was increased following treatment with OHT, but not its vehicle (Figures 2E and S2C) . Moreover, the luciferase activity driven by −71/+40 was lower than that driven by −224/+40 in the presence or absence of OHT ( Figure  2E ), suggesting that E2F-binding sites within −224/−71 of the Ror2 promoter might mediate E2F-induced expression of Ror2. Taken together, these data indicate that Ror2 is a direct transcriptional target of E2F1. Furthermore, bFGF-induced increase in Ror2 expression was detected in OHT-treated cells expressing E2F1-WT, but not E2F1-ΔC ( Figure 2F ), suggesting that E2F mediates bFGF-induced expression of Ror2 through a transcription-dependent mechanism.
| Ror2 promotes bFGF-induced G1/S phase transition in a Wnt5a signaling-independent manner
We then examined whether Ror2 plays an important role in regulating bFGF-induced cell cycle progression of NIH/3T3 cells. Protein levels of Ror2 in NIH/3T3 cells were increased following bFGF stimulation, and decreased by treating with two siRNAs directed against Ror2 (si-Ror2#1 and si-Ror2#2) ( Figure 3A ). si-Ror2#2 showed more efficient knockdown of Ror2 than si-Ror2#1. After serum deprivation for 24 hours, over 90% of cells were at G0/ G1 phase and they began to enter S phase within 12 hours after bFGF stimulation (data not shown). At 16 hours after 3418 | ENDO Et al.
F I G U R E 1 Expression of Ror2 is upregulated by serum-or bFGF-induced signaling in NIH/3T3 cells. A, NIH/3T3 cells cultured with
10% FBS were serum-starved in Opti-MEM for 24 hours, and then stimulated with bFGF for 6 hours. Expression of Ror2 and Ror1 mRNAs was analyzed by qRT-PCR. Relative expression values were determined by defining expression levels of Ror2 or Ror1 in cells cultured with 10% FBS as 1.0. The values are the mean ± SD of triplicate wells. *P < .05, **P < .01, n.s., not significant. Three independent experiments were performed. B, Serum-starved NIH/3T3 cells were stimulated with bFGF for the indicated periods (4, 8, 12, 16, 20 , and 24 hours). Expression of the indicated genes in both stimulated and unstimulated (0 hour) cells was analyzed by qRT-PCR. Relative expression values were determined by defining expression levels of the indicated genes in unstimulated cells as 1.0. The values are the mean ± SD of triplicate wells. C, NIH/3T3 cells were serum-starved in Opti-MEM for 24 hours, and then stimulated with bFGF along with doxorubicin (+Doxo, 0.2 μg/mL) or its vehicle (+DMSO) for 12 hours. Expression of the indicated genes was analyzed by qRT-PCR. Relative expression values were determined by defining expression levels of the indicated genes in unstimulated cells (serum free) as 1.0. The values are the mean ± SD of triplicate wells. ***P < .001, n.s., not significant. Two independent experiments were performed | 3419 ENDO Et al.
bFGF stimulation, among NIH/3T3 cells treated with control siRNA (si-Ctrl), only 31.1% of cells were at G1 phase and about half of cells were at G2/M phase (46.5%), while among the cells treated with si-Ror2, the proportions of cells at G1 phase were increased (si-Ror2#1, 41.8%; si-Ror2#2, 48 .5%) and those at G2/M phase were decreased (si-Ror2#1, 36.3%; si-Ror2#2, 32.0%) ( Figure 3B ). EdU-incorporation analysis revealed that entry into S phase was delayed in cells treated with si-Ror2 compared to those treated with si-Ctrl ( Figure 3C,D) . The asterisks indicate putative E2F-biding sites. B,C, NIH/3T3 cells infected with a control retrovirus (mock) or a retrovirus expressing either ERT2-E2F1-WT or −ΔC were serum-starved for 24 hours, and then treated with OHT for 4 hours or left untreated (−). Expression levels of Ror2 (B) and Ror1 (C) were analyzed by qRT-PCR. Relative expression values were determined by defining expression levels of the indicated genes in untreated mock-infected cells as 1.0. The values are the mean ± SD of triplicate wells. ***P < .001, n.s., not significant. Three independent experiments were performed. D, ChIP analysis was performed using serum-starved NIH/3T3 cells expressing ERT2-E2F1. Cross-linked chromatin was prepared from untreated cells (−) or cells treated with OHT for 4 hours, and subjected to co-immunoprecipitation with either rabbit anti-E2F1 antibody (E2F1 Ab) or isotype-matched control (irrelevant) IgG (Ctrl IgG), followed by qRT-PCR analysis using a primer set specific for mouse Ror2 promoter. The values are the mean ± SD of triplicate wells. **P < .01, n.s., not significant. Two independent experiments were performed. E, Luciferase activities in NIH/3T3 cells transiently transfected with control luciferase reporter vector (mock) or a luciferase reporter vector containing either −224/+40 or −71/+40 fragment of mouse Ror2 promoter region, followed by treatment with OHT for 4 hours or left untreated (−), were measured. The values are the mean ± SD of triplicate wells. ***P < .001, n.s., not significant. Two independent experiments were performed. F, NIH/3T3 cells infected with a control retrovirus (mock) or a retrovirus expressing either ERT2-E2F1-WT or −ΔC were serum-starved for 24 hours, treated with OHT for 2 hours, and then further stimulated with bFGF for 4 hours or left untreated (−). Expression of Ror2 was analyzed by qRT-PCR. Relative expression values were determined by defining expression level of Ror2 in untreated mock-infected cells as 1.0. The values are the mean ± SD of triplicate wells. *P < .05, **P < .01, n.s., not significant. Two independent experiments were performed Ror2 has been shown to act as a receptor for Wnt5a in NIH/3T3 cells, thereby regulating their directional cell migration by activating noncanonical Wnt pathway. 11 It was found that phosphorylation levels of Dvl2, a downstream effector molecule in the Wnt5a-Ror2 signaling, was increased in the cells treated with recombinant Wnt5a (rWnt5a), and 
F I G U R E 3 Expression of Ror2 is required for bFGF-induced G1/S phase transition of NIH/3T3 cells. A, Ror2 and β-actin proteins in cell
lysates from serum-starved NIH/3T3 cells treated with either Ror2 siRNAs (si-Ror2#1 and si-Ror2#2) or control siRNA (si-Ctrl), followed by stimulation with bFGF for 12 hours or left untreated, were measured by Western blotting with anti-Ror2 or anti-β-actin antibodies, respectively. Representative data from at least three independent experiments are shown. B, NIH/3T3 cells treated with si-Ror2#1, si-Ror2#2 or si-Ctrl were serum-starved for 24 hours, and then stimulated with bFGF for 16 hours. DNA content was determined by flow-cytometric analysis. DNA content histograms are shown with the percentage of cells in each cell cycle phase indicated. C, NIH/3T3 cells treated with either si-Ror2#2 or si-Ctrl were serum-starved for 24 hours, and then stimulated with bFGF for the indicated periods ( that rWnt5a-induced phosphorylation of Dvl2 was decreased in cells treated with si-Ror2 ( Figure S3A ). However, the proportions of EdU-incorporated cells were unaffected by treatment with rWnt5a ( Figure S3B ). Interestingly, at 12 hours after bFGF stimulation, the proportions of EdU-incorporated cells were decreased in the cells treated with si-Ror2, but were slightly increased in the cells treated with si-Wnt5a, compared to those treated with si-Ctrl ( Figure S3C) , while basal phosphorylation levels of Dvl2 were decreased by treatment with si-Wnt5a ( Figure S3D) . These results indicate that Ror2 promotes the cell cycle progression of NIH/3T3 cells irrespective of Wnt5a.
| Ror2 upregulates bFGF-induced expression of E2F-target genes
To unravel the molecular mechanism of Ror2-mediated cell cycle progression, we performed a genome-wide analysis of mRNA levels (RNA-seq) in bFGF-stimulated NIH/3T3 cells, and identified 175 overlapped gene transcripts differentially expressed in si-Ror2#1-treated cells and siRor2#2-treated cells compared to si-Ctrl-treated cells ( Figure 4A ). Of these, 63 genes were upregulated (Table S1 ), while 112 genes were downregulated (Table S2 ). GO and KEGG pathway analyses revealed that most downregulated DEGs were significantly enriched in the cell cycle process, including DNA replication initiation and DNA repair ( Figure 4B,C) . These groups of genes are mainly upregulated during the G1 to S phase transition of the cell cycle as transcriptional targets of E2Fs ( Figure S4 ). To confirm the results obtained by the genome-wide expression analysis, we carried out qRT-PCR analysis for a set of well-established E2F target genes. As expected, suppressed expression of Ror2 resulted in the inhibition of bFGF-induced upregulation of various E2F target genes, involved in DNA replication (CyclinE1, CyclinA2, Cdc6), cell survival (Birc5), and DNA repair (Brca1, Chk1, Rad51) ( Figure 5A ). E2F1, E2F2, and E2F3 have been classified in the same subgroup of the E2F-family of transcriptional activators and their expression has been shown to be transcriptionally upregulated by E2F itself. We observed that expression levels of E2F1, E2F2, and E2F3 were increased following bFGF stimulation and were suppressed by Ror2 knockdown ( Figure S5 ). These results indicate that Ror2 plays an important role in activating E2F during cell cycle progression from G1 to S phase in bFGF-treated NIH/3T3 cells.
| Ror2 promotes bFGF-induced G1/S phase transition by preventing FoxO3amediated inhibition of the Rb/E2F pathway
Although we failed to identify any apparently significant GO terms and KEGG pathways of the upregulated DEGs, KEGG pathway analysis revealed that upregulated genes by 1.5-fold or more in cells treated with si-Ror2#2 contain several FoxO target genes ( Figure S6 ). Thus, we further confirmed by qRT-PCR analysis that expression of multiple FoxO target genes, including Cyclin G2, p21 Cip1 , p27 Kip1 , Gadd45a, Sesn3, Bnip3, and Atg12, were indeed significantly increased in si-Ror2-treated cells compared to si-Ctrl-treated cells ( Figure 5B ). p21 Cip1 , p27 Kip1 , and Cyclin G2 have been shown to inactivate CDKs, and thereby inhibiting G1/S phase transition. 36, 37 In growth-arrested cells, the transcriptional activities of E2Fs are repressed by Rb, and growth factor-induced signaling mediates activation of CDKs, which in turn phosphorylate and inactivate Rb, leading to activation of E2F-driven transcription. [28] [29] [30] [31] [32] [33] Interestingly, it was found that bFGF-induced phosphorylation of Rb was suppressed concomitant with increased protein levels of p21 Cip1 and p27 Kip1 in si-Ror2-treated cells when compared to si-Ctrl-treated cells (Figure 6A,B) . Furthermore, the inhibitory effect of Ror2 knockdown on bFGF-induced G1/S phase transition was restored by simultaneously suppressed expression of p21 Cip1 and/or p27 Kip1 (Figure 6C-E) , but not Cyclin G2 (Figure S7A,B ), suggesting that Ror2 signaling might accelerate bFGF-induced activation of E2F-driven transcription by inhibiting FoxO transcription factor-mediated transcription of some if not all of its target genes, including p21 Cip1 and p27 Kip1 . We next tried to verify this possibility by suppressing both expression of Ror2 and FoxO3a simultaneously in bF-GF-stimulated NIH/3T3 cells. As shown in Figure 7A ,B, Ror2 knockdown resulted in increases in mRNA and protein levels of p21 Cip1 and p27 Kip1 , and in decreases in phosphorylation levels of Rb. Intriguingly, these alterations caused by Ror2 knockdown could be restored at least partly by simultaneously suppressed expression of FoxO3a (Figure 7A,B) .
F I G U R E 6
Inhibitory effects of Ror2 knockdown on bFGF-induced G1/S phase transition in NIH/3T3 cells are mediated by increased expression of p21 Cip1 and p27 Kip1 . A, Expression of the indicated proteins in cell lysates from serum-starved NIH/3T3 cells treated with either Ror2 siRNAs (si-Ror2#1 and si-Ror2#2) or control siRNA (si-Ctrl), followed by stimulation with bFGF for 12 hours, was measured by Western blotting with the indicated antibodies, respectively. p-Rb, phosphorylated Rb. Representative data from three independent experiments are shown. B, The histograms indicate the relative band intensities of p21 Cip1 and p27 Kip2 normalized by those of β-actin, and the relative band intensities of p-Rb normalized by those of total Rb. Data are expressed as mean ± SD of three independent experiments. *P < .05, **P < .01. C,D, NIH/3T3 cells treated with either p21 siRNAs (si-p21#1 and si-p21#2), p27 siRNA (si-p27) or control siRNA (si-Ctrl) were serum-starved for 24 hours, and then stimulated with bFGF for 8 hours. Knockdown efficiencies of si-p21 and si-p27 were evaluated by qRT-PCR. E, NIH/3T3 cells treated with si-Ror2#2 or si-Ctrl together with si-p21 and/or si-p27 were serum-starved for 24 hours, and then stimulated with bFGF for 12 hours in the presence of EdU. Proportions of EdU-positive cells were quantified. Data are expressed as mean ± SD of three independent experiments (>3000 cells/ experiments). *P < .05, **P < .01, ***P < .001 3424 | ENDO Et al.
F I G U R E 7
Suppressed expression of FoxO3a rescues the inhibitory effects of Ror2 knockdown on bFGF-induced G1/S phase transition in NIH/3T3 cells. A, NIH/3T3 cells treated with either Ror2 siRNAs (si-Ror2#1 and si-Ror2#2) or control siRNA (si-Ctrl) together with or without FoxO3a siRNA (si-FoxO3a) were serum-starved for 24 hours, and then stimulated with bFGF for 8 hours. Expression of the indicated genes was analyzed by qRT-PCR. Relative expression values were determined by defining expression levels of the indicated genes in si-Ctrl-treated cells as 1.0. The values are the mean ± SD of triplicate wells. *P < .05, **P < .01, ***P < .001, n.s., not significant. Two independent experiments were performed. B, The indicated proteins in cell lysates from serum-starved NIH/3T3 cells treated with si-Ror2#1, si-Ror2#2 or si-Ctrl together with or without si-FoxO3a, followed by stimulation with bFGF for 12 hours, were measured by Western blotting with the indicated antibodies, respectively. p-Rb, phosphorylated Rb. Representative data from three independent experiments are shown. C, NIH/3T3 cells treated with si-Ror2#1, si-Ror2#2 or si-Ctrl together with or without si-FoxO3a were serum-starved for 24 hours, and then stimulated with bFGF for 12 hours in the presence of EdU. Proportions of EdU-positive cells were quantified. Data are expressed as mean ± SD of three independent experiments (>3000 cells/experiments). *P < .05, ***P < .001, n.s., not significant | 3425 ENDO Et al.
Furthermore, the G1/S phase transition of NIH/3T3 cells treated with si-FoxO3a was marginally affected by treatment with si-Ror2 ( Figure 7C ). These results indicate that Ror2 might promote the cell cycle progression by preventing FoxO3a-mediated inhibition of the Rb/E2F pathway in NIH/3T3 cells.
PI3K-Akt pathway has been shown to inhibit Foxo3amediated transcription. 38 Indeed, treatment of NIH/3T3 cells with LY294002, a PI3K inhibitor, blocks its downstream Akt phophorylation, leading to increased expression of p21 Cip1 and p27 Kip1 (Figure S8A ), and inhibition of bF-GF-induced cell cycle progression ( Figure S8B ). Thus, we examined whether Ror2 signaling affects phosphorylation levels of Akt in bFGF-stimulated NIH/3T3 cells. It was found that phosphorylation levels of Akt were significantly decreased by suppressed expression of Ror2 (Figure 8A,B) . Akt phosphorylates FoxO3a, thereby translocating FoxO3a from the nucleus to the cytoplasm. Immunocytochemical analyses revealed that nuclear localization of FoxO3a was significantly increased by Ror2 knockdown as well as PI3K inhibition (Figures 8C and S8C) . Collectively, these findings support a notion that Ror2 signaling might promote the G1/S phase transition by suppressing FoxO3a-mediated negative regulation of E2F-driven cell cycle gene transcription through activation of PI3K-Akt pathway in bFGF-stimulated NIH/3T3 cells.
F I G U R E 8 Suppressed expression of Ror2 in bFGF-stimulated NIH/3T3 cells results in reduced phosphorylation of Akt and increased
nuclear localization of FoxO3a. A, Expression of the indicated proteins in cell lysates from serum-starved NIH/3T3 cells treated with either Ror2 siRNAs (si-Ror2#1 and si-Ror2#2) or control siRNA (si-Ctrl), followed by stimulation with bFGF for 12 hours, was measured by Western blotting with the indicated antibodies, respectively. p-Akt, phosphorylated Akt. Representative data from three independent experiments are shown. B, The histograms indicate the relative band intensities of p-Akt normalized by those of total Akt. Data are expressed as mean ± SD of three independent experiments. *P < .05, **P < .01. C, Immunofluorescence analysis for FoxO3a in cells treated with the indicated siRNAs, followed by stimulation with bFGF for 12 hours. Nuclei were visualized with DAPI. Scale bar, 50 μm. Graph shows the ratio of mean fluorescence intensity of nuclear FoxO3a to cytoplasmic FoxO3a. Data are expressed as mean ± SD of 9 different microscopic fields (about 50 cells/field) per sample. Two independent experiments were performed. **P < .01, ***P < .001
| DISCUSSION
Although accumulating evidence demonstrates that Ror2 mediates to regulate the cell proliferation as well as the cellular polarity and migration, little is known about the molecular mechanism of Ror2-mediated cell cycle progression. We have previously shown that expression of Ror2 in quiescent astrocytes is increased following bFGF stimulation, and that Ror2 signaling plays a critical role in promoting the cell cycle progression from G1 to S phase in bFGF-stimulated astrocytes. However, it remains entirely unknown how expression of Ror2 is induced by bFGF stimulation and how Ror2 mediates the regulation of bFGF-induced G1/S phase transition. In this study, we show for the first time that Ror2 gene is transcriptionally activated by E2F1, resulting in increased expression of Ror2, and that induced Ror2 in turn mediates further transcriptional activation of E2F target genes, involved in DNA replication and DNA repair in bFGF-stimulated NIH/3T3 cells. Moreover, induced Ror2 also mediates transcriptional inhibition of FoxO3a target genes, including genes encoding Cdk inhibitors, p21 Cip1 and p27 Kip1 , thereby accelerating G1/S phase transition of bFGF-stimulated NIH/3T3 cells.
E2F1, a major regulator of cell cycle progression, is activated by not only bFGF but also other growth factors such as EGF. Indeed, we have shown that expression of Ror2 is induced by EGF stimulation in cultured astrocytes during their cell cycle progression. 23 Furthermore, Ror2 is expressed highly in embryonic tissues that contain abundantly proliferating cells, indicating that E2F1-induced transcriptional activation of Ror2 might also be involved in the expression of Ror2 in these proliferating cells during embryogenesis. E2F1 is also activated strongly in cancer cells through various mechanisms, including activation of oncogenes and inhibition of tumor suppressor genes. 39 It has been shown that Ror2 is expressed highly in lung adenocarcinoma cells harboring p53 loss-of-function mutations 40 and in human papillomavirus (HPV)-positive head and neck squamous cell carcinoma, where HPV oncogenic protein E7 represses Rb. 41 Interestingly, multiple putative E2F binding sites are found within the nucleotide sequences at regions approximately 200 bp upstream of the Ror2 genes, that are conserved highly between mouse and human. Therefore, it can be envisaged that E2F1 might also be involved in induced expression of Ror2 in highly proliferative cancer cells with p53 mutations or infected with HPV. Further studies will be required to clarify a possible involvement of E2F1-induced expression of Ror2 in embryogenesis and/or progression of cancer cells.
Although Ror1 and Ror2 exhibit similar expression patterns and functional redundancies in various tissues/organs during early embryogenesis, they also show distinct expression patterns and pleiotropic functions in several cell types, tissues, and organs in adult animals as well as embryos. 15, 20, 42 Here, we show that expression levels of Ror1 are affected by neither bFGF stimulation nor E2F1 activation in NIH/3T3 cells, indicating that differential responsiveness of Ror1 and Ror2 promoters to E2F1 might contribute to determine at least partly cell type-specific expression of Ror1 and/or Ror2.
Ror1 has been shown to regulate the cell proliferation and survival by mediating activation of PI3K-Akt pathway. [43] [44] [45] [46] FoxO transcription factors are translocated from the nucleus to the cytoplasm after phosphorylation by Akt, resulting in inhibition of its target gene expression. Indeed, Ror1-Akt pathway has been shown to promote phosphorylation and translocation of FoxO1 in lung adenocarcinoma cells. 44 Therefore, it is possible that Ror2 also mediates to promote phosphorylation and inhibition of FoxO3a by activating Akt. Indeed, we found that phosphorylation levels of Akt were decreased and nuclear localization of FoxO3a was increased by suppressed expression of Ror2 in bFGF-stimulated NIH/3T3 cells. Furthermore, accumulating evidence demonstrates that Ror2 signaling activates PI3K-Akt pathway in cancer cells, including osteosarcoma and myeloma, 47, 48 although the molecular basis of PI3K-Akt activation by Ror2 signaling still remains unclear. Thus, it would be of interest to address a question of how Ror2 regulates PI3K-Akt pathway in these proliferating cells.
Since Ror2 can mediate promotion of bFGF-induced cell cycle progression in a Wnt5a-independent manner ( Figure  S2 , and ( 23 )), it is important to clarify how Ror2 can be activated in bFGF-stimulated cells. In adult hippocampal neural stem cells, Ror2 can be activated to promote their proliferation through the interaction with Lrp4 upon stimulation by Agrin, secreted from excitatory neurons. 22 In this case, Agrin stimulation increases tyrosine phosphorylation levels of Ror2 in neural stem cells. 22 Interestingly, Ror1 has been shown to be tyrosine phosphorylated by c-Met to promote Met-driven cancer cell proliferation, 49 indicating that tyrosine phosphorylation of Ror1 and Ror2 might be involved in regulating cell proliferation irrespective of Wnt5a. Further experiments will be required to unravel a possible involvement of tyrosine phosphorylation of Ror2 in regulating cell cycle progression of bFGF-stimulated cells.
Positive feedback circuits consisting of E2Fs and their transcriptional target gene products, such as Cyclin E, play important roles in regulating G1/S phase transition. 33 In this study, we show that E2F1 induces expression of Ror2, and that Ror2 mediates to promote E2F-driven transcription, indicating that E2F1-Ror2 signaling might also act as a positive feedback loop to promote G1/S phase transition. Future studies will reveal critical roles of E2F1-Ror2 signaling in regulating the cell cycle progression of proliferating astrocytes in the injured brains and/or of proliferative cancer cells. It can be envisaged that E2F1-Ror2 signaling might be a suitable target to develop novel therapeutic approaches to promote brain repair following injury and to inhibit cancer progression.
